Divi's Laboratories Limited (DIVISLAB) Stock Forecast & Price Target

Compare

5 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DIVISLAB Analyst Ratings

Moderate Buy

2 Buy

0 Hold

1 Sell

Based on 3 analysts giving stock ratings to

Divi's

Laboratories Limited

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DIVISLAB Stock 12 Month Forecast

Average Price Target

₹6,866.67

▲(3.99% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Divi's Laboratories Limited in the last 3 months. The average price target is ₹6,866.67 with a high forecast of ₹7,800.00 and a low forecast of ₹5,400.00. The average price target represents a 3.99% change from the last price of ₹6,603.05.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5398":"₹5,398","7801":"₹7,801","5998.75":"₹5,998.8","6599.5":"₹6,599.5","7200.25":"₹7,200.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7800,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹8K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6866.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹7K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5400,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹5.40K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5398,5998.75,6599.5,7200.25,7801],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5710.7,5871.415384615384,6032.130769230769,6192.846153846153,6353.5615384615385,6514.276923076923,6674.992307692308,6835.707692307692,6996.423076923077,7157.138461538461,7317.8538461538465,7478.569230769231,7639.284615384615,{"y":7800,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5710.7,5799.620769230769,5888.541538461538,5977.462307692307,6066.383076923077,6155.303846153846,6244.224615384615,6333.1453846153845,6422.066153846154,6510.986923076923,6599.907692307692,6688.828461538462,6777.749230769231,{"y":6866.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5710.7,5686.8,5662.9,5639,5615.099999999999,5591.2,5567.3,5543.4,5519.5,5495.6,5471.7,5447.8,5423.9,{"y":5400,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5399.22,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5867.19,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6221.87,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6221.87,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6043.44,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5550.63,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5452.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5523.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6058.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6819.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6359,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6091.05,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5710.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target₹7,800

Average Price Target₹6,867

Lowest Price Target₹5,400

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Damayanti Kerai

HSBC

₹7,700→₹7,400

Buy

12.07%

Upside

Reiterated

10/14/25

Divi's Laboratories Limited (DIVISLAB) Gets a Buy from HSBCHSBC analyst Damayanti Kerai lowered the price target on Divi's Laboratories Ltd (DIVI:IN) to INR7,400.00 (from INR7,700.00) while maintaining a Buy rating.

Alankar Garude

Kotak Mahindra

₹5,400

Sell

-18.22%

Downside

Reiterated

09/29/25

Kotak Mahindra Reaffirms Their Sell Rating on Divi's Laboratories Limited (DIVISLAB)

Bansi Desai

J.P. Morgan

₹7,800

Buy

18.13%

Upside

Initiated

09/19/25

JPMorgan Starts Divi's Laboratories Ltd (DIVI:IN) at OverweightJPMorgan analyst Bansi Desai initiates coverage on Divi's Laboratories Ltd (DIVI:IN) with a Overweight rating and a price target of INR7,800.00.

Dhawal Khut

Jefferies

₹6,750→₹7,150

Buy

8.28%

Upside

Upgraded

08/25/25

Jefferies Upgrades Divi's Laboratories Ltd (DIVI:IN) to BuyJefferies analyst Dhawal Khut upgraded Divi's Laboratories Ltd (DIVI:IN) from Hold to Buy with a price target of INR7,150.00 (from INR6,750.00).

Abdulkader Puranwala

ICICI Securities

₹5,610→₹5,400

Sell

-18.22%

Downside

Reiterated

08/07/25

ICICI Securities Reaffirms Their Sell Rating on Divi's Laboratories Limited (DIVISLAB)

Shyam Srinivasan

Goldman Sachs

₹5,800→₹6,375

Hold

-3.45%

Downside

Reiterated

07/15/25

Goldman Sachs Reaffirms Their Hold Rating on Divi's Laboratories Limited (DIVISLAB)

Neha Manpuria

Bank of America Securities

₹6,800→₹7,150

Buy

8.28%

Upside

Reiterated

05/19/25

Divi's Laboratories Ltd (DIVI:IN) PT Raised to INR7,150 at BofA SecuritiesBofA Securities analyst Neha Manpuria raised the price target on Divi's Laboratories Ltd (DIVI:IN) to INR7,150.00 (from INR6,800.00) while maintaining a Buy rating.

Vivek Agrawal CFA

Citi

₹7,050→₹7,750

Buy

17.37%

Upside

Reiterated

05/19/25

Divi's Laboratories Ltd (DIVI:IN) PT Raised to INR7,750 at CitiCiti analyst Vivek Agrawal raised the price target on Divi's Laboratories Ltd (DIVI:IN) to INR7,750.00 (from INR7,050.00) while maintaining a Buy rating.

Binay Singh

Morgan Stanley

₹7,141→₹7,185

Buy

8.81%

Upside

Reiterated

05/18/25

Divi's Laboratories Ltd (DIVI:IN) PT Raised to INR7,185 at Morgan StanleyMorgan Stanley analyst Binay Singh raised the price target on Divi's Laboratories Ltd (DIVI:IN) to INR7,185.00 (from INR7,141.00) while maintaining a Overweight rating.

Kunal Dhamesha

Macquarie

₹7,400

Buy

12.07%

Upside

Reiterated

03/28/25

Macquarie Reiterates Outperform Rating on Divi's Laboratories Ltd (DIVI:IN)Macquarie analyst Kunal Dhamesha reiterated an Outperform rating and INR7,400.00 price target on Divi's Laboratories Ltd (DIVI:IN).

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Damayanti Kerai

HSBC

₹7,700→₹7,400

Buy

12.07%

Upside

Reiterated

10/14/25

Alankar Garude

Kotak Mahindra

₹5,400

Sell

-18.22%

Downside

Reiterated

09/29/25

Kotak Mahindra Reaffirms Their Sell Rating on Divi's Laboratories Limited (DIVISLAB)

Bansi Desai

J.P. Morgan

₹7,800

Buy

18.13%

Upside

Initiated

09/19/25

Dhawal Khut

Jefferies

₹6,750→₹7,150

Buy

8.28%

Upside

Upgraded

08/25/25

Abdulkader Puranwala

ICICI Securities

₹5,610→₹5,400

Sell

-18.22%

Downside

Reiterated

08/07/25

ICICI Securities Reaffirms Their Sell Rating on Divi's Laboratories Limited (DIVISLAB)

Shyam Srinivasan

Goldman Sachs

₹5,800→₹6,375

Hold

-3.45%

Downside

Reiterated

07/15/25

Goldman Sachs Reaffirms Their Hold Rating on Divi's Laboratories Limited (DIVISLAB)

Neha Manpuria

Bank of America Securities

₹6,800→₹7,150

Buy

8.28%

Upside

Reiterated

05/19/25

Vivek Agrawal CFA

Citi

₹7,050→₹7,750

Buy

17.37%

Upside

Reiterated

05/19/25

Binay Singh

Morgan Stanley

₹7,141→₹7,185

Buy

8.81%

Upside

Reiterated

05/18/25

Kunal Dhamesha

Macquarie

₹7,400

Buy

12.07%

Upside

Reiterated

03/28/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Divi's Laboratories Limited

1 Month

xxx

Success Rate

2/3 ratings generated profit

Average Return

-2.40%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of -2.40% per trade.

3 Months

xxx

Success Rate

2/2 ratings generated profit

Average Return

+13.15%

reiterated a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +13.15% per trade.

1 Year

Kunal DhameshaMacquarie

Success Rate

2/2 ratings generated profit

Average Return

+8.00%

reiterated a buy rating 9 months ago

Copying Kunal Dhamesha's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +8.00% per trade.

2 Years

xxx

Success Rate

2/2 ratings generated profit

Average Return

+8.00%

reiterated a xxx

rating 9 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +8.00% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DIVISLAB Analyst Recommendation Trends

Rating

May 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DIVISLAB has received 4 Buy Ratings, 7 Hold Ratings, and 3 Sell Ratings. DIVISLAB average Analyst price target in the past 3 months is 6,866.67.

Each month's total comprises the sum of three months' worth of ratings.

DIVISLAB Financial Forecast

DIVISLAB Earnings Forecast

Next quarter’s earnings estimate for DIVISLAB is ₹23.50 with a range of ₹20.57 to ₹25.55. The previous quarter’s EPS was ₹25.97. DIVISLAB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year DIVISLAB has Performed in-line its overall industry.

DIVISLAB Sales Forecast

Next quarter’s sales forecast for DIVISLAB is ₹27.37B with a range of ₹26.99B to ₹27.72B. The previous quarter’s sales results were ₹27.15B. DIVISLAB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year DIVISLAB has Performed in-line its overall industry.

DIVISLAB Stock Forecast FAQ

What is IN:DIVISLAB’s average 12-month price target, according to analysts?

Based on analyst ratings, Divi's Laboratories Limited’s 12-month average price target is 6,866.67.

What is IN:DIVISLAB’s upside potential, based on the analysts’ average price target?

Divi's Laboratories Limited has 3.99% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Divi's Laboratories Limited a Buy, Sell or Hold?

Divi's Laboratories Limited has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 1 sell ratings.

What is Divi's Laboratories Limited’s share price target?

The average share price target for Divi's Laboratories Limited is 6,866.67. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ₹7,800.00 ,and the lowest forecast is ₹5,400.00. The average share price target represents 3.99% Increase from the current price of ₹6,603.05.

What do analysts say about Divi's Laboratories Limited?

Divi's Laboratories Limited’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of Divi's Laboratories Limited?

To buy shares of IN:DIVISLAB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Divi's Laboratories Limited (DIVISLAB) Stock Forecast & Price Target

DIVISLAB Analyst Ratings

DIVISLAB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Divi's Laboratories Limited

DIVISLAB Analyst Recommendation Trends

DIVISLAB Financial Forecast

DIVISLAB Earnings Forecast

DIVISLAB Sales Forecast

DIVISLAB Stock Forecast FAQ

Detailed List of Analyst Forecasts